Why Haemonetics Stock Is Drawing Investor Attention

Haemonetics (HAE) has come onto investors' radar after a sharp share price pullback, with the stock showing negative returns over the past month and past 3 months despite positive annual revenue and net income growth.

The recent pullback fits into a weaker trend, with a 30 day share price return of about 20% and a 3 year total shareholder return of roughly a 29% decline, suggesting momentum has been fading despite revenue and net income growth.

If Haemonetics' volatility has you reassessing opportunities, this could be a good moment to broaden your search and check out 25 healthcare AI stocks as potential candidates to research next.

With Haemonetics trading around $57.76 and sitting at a discount to both analysts' price targets and some intrinsic value estimates, investors may ask whether this reflects a mispriced healthcare technology company or whether the market is already factoring in its growth.

Most Popular Narrative: 37% Undervalued

Haemonetics' most followed narrative puts fair value around $91.70 per share, well above the recent $57.76 close, framing the stock as materially discounted.

Enterprise-wide portfolio transformation, highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions, is driving substantial gross and operating margin expansion (guidance of 26 to 27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.

Curious how margin guidance, earnings forecasts and a mid-teens future P/E all feed into that fair value? The full narrative lays out the step by step math.

Result: Fair Value of $91.70 (UNDERVALUED)

However, this story can break if reliance on a few U.S. focused products persists, and if competition or ongoing VASCADE challenges start to chip away at earnings stability.

Next Steps

Given the mix of caution and optimism in this story, it makes sense to move quickly, review the facts for yourself, and weigh up 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop with one company. Use this moment to widen your watchlist, compare different types of opportunities, and see what else stands out on the screener.

• Spot potential value opportunities early by scanning 54 high quality undervalued stocks that pass a set of balance sheet and cash flow checks.
• Prioritise resilience by reviewing 83 resilient stocks with low risk scores that score well on our risk framework and may offer a steadier ride.
• Hunt for less crowded opportunities through our screener containing 24 high quality undiscovered gems that combine solid fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.